Skip to content
← Full study record

NCT04892446 · MORE INFO

Limitations, agreements, and source contact

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2025-05-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: * The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or * The study has been completed at all study sites for at least 2 years
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and program closure. Due to early termination of the study, reported findings should be interpreted in the context of the study's early closure.
point Of Contact
email
GileadClinicalTrials@gilead.com
organization
Gilead Sciences
phone
1-833-445-3230 (GILEAD-0)
title
Gilead Clinical Study Information Center
Complete source fields
certain Agreement
other Details
After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: * The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or * The study has been completed at all study sites for at least 2 years
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and program closure. Due to early termination of the study, reported findings should be interpreted in the context of the study's early closure.
point Of Contact
email
GileadClinicalTrials@gilead.com
organization
Gilead Sciences
phone
1-833-445-3230 (GILEAD-0)
title
Gilead Clinical Study Information Center

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice